Cargando…
Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease
BACKGROUND: Recombinant von Willebrand factor (rVWF, vonicog alfa) is a purified VWF concentrate produced from Chinese hamster ovary cells. rVWF is not exposed to the VWF-cleaving protease ADAMTS13 and so is not subject to proteolytic degradation of large (L) and ultra-large (UL) VWF multimers by th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673800/ https://www.ncbi.nlm.nih.gov/pubmed/36405429 http://dx.doi.org/10.2147/JBM.S377126 |
_version_ | 1784833024860356608 |
---|---|
author | Gritsch, Herbert Schrenk, Gerald Weinhappl, Nina Mellgård, Björn Ewenstein, Bruce Turecek, Peter L |
author_facet | Gritsch, Herbert Schrenk, Gerald Weinhappl, Nina Mellgård, Björn Ewenstein, Bruce Turecek, Peter L |
author_sort | Gritsch, Herbert |
collection | PubMed |
description | BACKGROUND: Recombinant von Willebrand factor (rVWF, vonicog alfa) is a purified VWF concentrate produced from Chinese hamster ovary cells. rVWF is not exposed to the VWF-cleaving protease ADAMTS13 and so is not subject to proteolytic degradation of large (L) and ultra-large (UL) VWF multimers by that enzyme. PURPOSE: To compare the structure and function of rVWF with the human plasma-derived VWF [pdVWF] concentrates Haemate P(®)/Humate-P(®), Voncento(®), Wilate(®)/Eqwilate(®), and Wilfactin(®)/Willfact(®); to investigate the relationship between VWF multimeric pattern and VWF:ristocetin cofactor (VWF:RCo) activity through population pharmacokinetic (PK) modeling in patients with severe von Willebrand disease (VWD) treated with rVWF. METHODS: Analyses included VWF:RCo activity, VWF:collagen-binding activity, VWF:platelet glycoprotein Ib receptor binding, factor VIII (FVIII) binding capacity, and VWF-mediated platelet adhesion under flow conditions. VWF multimeric structure was determined by agarose gel electrophoresis. Population PK models describing the activity-time profile of small, medium, and L/UL multimers following intravenous administration of rVWF in patients with severe VWD were developed. RESULTS: Findings demonstrate that rVWF contains a non-degraded VWF multimer pattern including the UL multimers not present in pdVWF concentrates. rVWF displayed higher specific platelet-binding activity, and faster mediation of platelet adhesion to collagen under shear stress versus pdVWF concentrates. rVWF also demonstrated higher FVIII binding capacity than Haemate P(®), Voncento(®) and Wilate(®). Modeling provided evidence that VWF:RCo activity in patients with severe VWD treated with rVWF is associated with L/UL VWF multimers in the circulation. CONCLUSIONS: Findings suggest that the L and UL multimers preserved in rVWF contribute to high biological activity and might be important for providing hemostatic efficacy. |
format | Online Article Text |
id | pubmed-9673800 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-96738002022-11-19 Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease Gritsch, Herbert Schrenk, Gerald Weinhappl, Nina Mellgård, Björn Ewenstein, Bruce Turecek, Peter L J Blood Med Original Research BACKGROUND: Recombinant von Willebrand factor (rVWF, vonicog alfa) is a purified VWF concentrate produced from Chinese hamster ovary cells. rVWF is not exposed to the VWF-cleaving protease ADAMTS13 and so is not subject to proteolytic degradation of large (L) and ultra-large (UL) VWF multimers by that enzyme. PURPOSE: To compare the structure and function of rVWF with the human plasma-derived VWF [pdVWF] concentrates Haemate P(®)/Humate-P(®), Voncento(®), Wilate(®)/Eqwilate(®), and Wilfactin(®)/Willfact(®); to investigate the relationship between VWF multimeric pattern and VWF:ristocetin cofactor (VWF:RCo) activity through population pharmacokinetic (PK) modeling in patients with severe von Willebrand disease (VWD) treated with rVWF. METHODS: Analyses included VWF:RCo activity, VWF:collagen-binding activity, VWF:platelet glycoprotein Ib receptor binding, factor VIII (FVIII) binding capacity, and VWF-mediated platelet adhesion under flow conditions. VWF multimeric structure was determined by agarose gel electrophoresis. Population PK models describing the activity-time profile of small, medium, and L/UL multimers following intravenous administration of rVWF in patients with severe VWD were developed. RESULTS: Findings demonstrate that rVWF contains a non-degraded VWF multimer pattern including the UL multimers not present in pdVWF concentrates. rVWF displayed higher specific platelet-binding activity, and faster mediation of platelet adhesion to collagen under shear stress versus pdVWF concentrates. rVWF also demonstrated higher FVIII binding capacity than Haemate P(®), Voncento(®) and Wilate(®). Modeling provided evidence that VWF:RCo activity in patients with severe VWD treated with rVWF is associated with L/UL VWF multimers in the circulation. CONCLUSIONS: Findings suggest that the L and UL multimers preserved in rVWF contribute to high biological activity and might be important for providing hemostatic efficacy. Dove 2022-11-14 /pmc/articles/PMC9673800/ /pubmed/36405429 http://dx.doi.org/10.2147/JBM.S377126 Text en © 2022 Gritsch et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Gritsch, Herbert Schrenk, Gerald Weinhappl, Nina Mellgård, Björn Ewenstein, Bruce Turecek, Peter L Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease |
title | Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease |
title_full | Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease |
title_fullStr | Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease |
title_full_unstemmed | Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease |
title_short | Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease |
title_sort | structure and function of recombinant versus plasma-derived von willebrand factor and impact on multimer pharmacokinetics in von willebrand disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673800/ https://www.ncbi.nlm.nih.gov/pubmed/36405429 http://dx.doi.org/10.2147/JBM.S377126 |
work_keys_str_mv | AT gritschherbert structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease AT schrenkgerald structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease AT weinhapplnina structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease AT mellgardbjorn structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease AT ewensteinbruce structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease AT turecekpeterl structureandfunctionofrecombinantversusplasmaderivedvonwillebrandfactorandimpactonmultimerpharmacokineticsinvonwillebranddisease |